AstraZeneca latest drugmaker to challenge Medicare drug price negotiation
cagkansayin

AstraZeneca (NASDAQ:AZN) has joined other pharmaceutical companies in challenging CMS' plan to start negotiating prices for some of the most expensive drugs covered by Medicare.
The UK-based drugmaker filed its lawsuit in a Delaware federal court.
AstraZeneca (AZN) EVP, Oncology Business Unit David Fredrickson told the Financial Times that the negotiations would have a negative impact on development of treatments for rare diseases.

Bristol-Myers Squibb (BMY), Johnson & Johnson (JNJ), and Merck (MRK) are among the other drugmakers challenging the Inflation Reduction Act's Medicare price negotiation provisions.


More on Medicare price negotiation

Drugs picked for Medicare price negotiations to be announced on Tuesday â Politico
Lawsuits unlikely to hinder Medicare drug price negotiations â UBS
AARP, Public Citizen file briefs in Medicare drug price negotiations case
J&J becomes latest Big Pharma to sue over Medicare drug pricing
Medicare revises guidance on drug price negotiations amid lawsuits